



## Recent Advances in Radiopharmaceutics

Guest Editor:

**Dr. Masato Kobayashi**

School of Health Sciences,  
Institute of Medical,  
Pharmaceutical and Health  
Sciences, Kanazawa University,  
Kanazawa, Japan

Deadline for manuscript  
submissions:

**closed (10 September 2022)**

### Message from the Guest Editor

Dear Colleagues,

Development of radiopharmaceuticals is important for diagnosis and/or radionuclide therapy in nuclear medicine with positron emission tomography (PET) and single photon emission computed tomography (SPECT). It also has translational potential from preclinical to clinical study in fields of oncology, neurodegenerative diseases, cardiovascular disease, etc. for personalized medicine. Integrative imaging and therapy in combination with other modalities, magnetic resonance imaging, ultrasonography, and near infrared imaging, etc., may move the personalized medicine further. In addition, advances of PET and SPECT scanners emphasize the usefulness of radiopharmaceuticals.

This Special Issue will focus on synthesis and evaluation of new radiopharmaceuticals, other applications of radiopharmaceuticals for clinical studies, and the combination of a radionuclide with other modalities. Novel PET and SPECT machines are also targeted.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma